Avenzo gained ex-China global rights to AVZO-021 (formerly ARTS-021), a selective CDK2 inhibitor, plus an exclusive option for an undisclosed preclinical programme.
Allorion will receive $40 million upfront and is eligible for development, regulatory and commercial milestones for both programs, which could total more than $1 billion, as well as tiered royalties.
And the deal comes just months after BeiGene grabbed its own CDK2 inhibitor. In November, BeiGene agreed to pay up to $1.3 billion for Ensem Therapeutics’ oral compound, ETX-197.